Characterization of an animal model of postmenopausal cardiac hypertrophy and novel mechanisms responsible for cardiac decompensation using ovariectomized pressure-overloaded rats

Menopause

Volumn 17, Issue 1, 2010, Pages 213-221

  Bhuiyan, Md Shenuarin ^a   Fukunaga, Kohji ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

Akt; Endothelial nitric oxide synthase; Myocardial hypertrophy; Ovariectomy; Postmenopause

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; ISOPRENALINE; PROTEIN KINASE B;

BETA ADRENERGIC STIMULATION; BODY WEIGHT; CARDIOVASCULAR DISEASE; ENZYME ACTIVITY; ESTROGEN BLOOD LEVEL; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; HEART WEIGHT; HYPERTENSION; LUNG WEIGHT; MEAN ARTERIAL PRESSURE; MORTALITY; NONHUMAN; OVARIECTOMY; PATHOPHYSIOLOGY; PHENOTYPE; POSTMENOPAUSE; PROTEIN EXPRESSION; REVIEW;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; DISEASE MODELS, ANIMAL; ESTROGENS; FEMALE; HEART FAILURE; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; OVARIECTOMY; POSTMENOPAUSE; PROTO-ONCOGENE PROTEINS C-AKT; RATS; SIGNAL TRANSDUCTION; VENTRICULAR REMODELING;

EID: 74549196301     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181b57489     Document Type: Review

References (76)

1. Belchetz PE. Hormonal treatment of postmenopausal women. N Engl J Med 1994;330:1062-1071.
2. Turgeon JL, McDonnell DP, Martin KA, Wise PM. Hormone therapy: physiological complexity belies therapeutic simplicity. Science 2004; 304:1269-1273.
3. Gorodeski GI. Update on cardiovascular disease in post-menopausal women. Best Pract Res Clin Obstet Gynaecol 2002;16:329-355.
4. Mosca L, Manson JE, Sutherland SE, Langer RD, Manolio T, Barrett-Connor E. Cardiovascular disease in women: a statement for healthcare professionals from the American Heart Association. Writing Group. Circulation 1997;96:2468-2482.
5. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med 1976;85:447-452.
6. Howe HL. Age-specific hysterectomy and oophorectomy prevalence rates and the risks for cancer of the reproductive system. Am J Public Health 1984;74:560-563.
7. Howard BV, Kuller L, Langer R, et al. Risk of cardiovascular disease by hysterectomy status, with and without oophorectomy: the Women's Health Initiative Observational Study. Circulation 2005;111:1462-1470.
8. Melton LJ 3rd, Bergstralha QEJ, Malkasian GD, O'Fallon WM. Bilateral oophorectomy trends in Olmsted County, Minnesota, 1950-1987. Epidemiology 1991 2 149-152.
9. Whiteman MK, Hillis SD, Jamieson DJ, et al. Inpatient hysterectomy surveillance in the United States, 2000-2004. Am J Obstet Gynecol 2008;198:e1-e7.
10. Keshavarz H, Hillis SD, Kieke BA, Marchbanks PA. Hysterectomy surveillanceVUnited States, 1994-1999. MMWR Surveill Summ 2002; 51:1-8.
11. Shuster LT, Gostout BS, Grossardt BR, Rocca WA. Prophylactic oophorectomy in pre-menopausal women and long term healthVa review. Menopause Int 2008;14:111-116.
12. Lobo RA. Surgical menopause and cardiovascular risks. Menopause 2007;14:562-566.
13. Lokkegaard E, Jovanovic Z, Heitmann BL, et al. The association between early menopause and risk of ischaemic heart disease: influence of hormone therapy. Maturitas 2006;53:226-233.
14. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-1477.
15. Dubey RK, Imthurn B, Barton M, Jackson EK. Vascular consequences of menopause and hormone therapy: importance of timing of treatment and type of estrogen. Cardiovasc Res 2005;66:295-306.
16. American Heart Association. Heart Disease and Stroke Statistics: 2005 Statistical Supplement. Dallas, TX: American Heart Association, 2005.
17. Leinwand LA. Sex is a potent modifier of the cardiovascular system. J Clin Invest 2003;112:302-307.
18. Hayward CS, Kelly RP, Collins P. The roles of gender, the menopause and hormone replacement on cardiovascular function. Cardiovasc Res 2000;46:28-49.
19. Patten RD, Pourati I, Aronovitz M, et al. 17 A-Estradiol differentially affects left ventricular and cardiomyocyte hypertrophy following myo-cardial infarction and pressure overload. J Card Fail 2008;14:245-253.
20. van Eickels M, Grohe C, Cleutjens JP, Janssen BJ, Wellens HJ, Doevendans PA. 17 A-Estradiol attenuates the development of pressure-overload hypertrophy. Circulation 2001;104:1419-1423.
21. Thorndike EA, Turner AS. In search of an animal model for post-menopausal diseases. Front Biosci 1998;3:c17-c26.
22. The North American Menopause Society. Menopause Practice: A Clinician's Guide. Mayfield Heights, OH: NAMS, 2004. Available at http://www.menopause.org.
23. Timaras P, Quay W, Vernadakis A, eds. Hormones and Aging. Boca Raton, FL: CRC Press, 1995.
24. Downs JL, Wise PM. The role of the brain in female reproductive aging. Mol Cell Endocrinol 2009;299:32-38.
25. Meites J, Lu JKH. Reproductive aging and neuroendocrine function. In: Charlton HM, editor. Oxford Reviews of Reproductive Biology. New York: Oxford University Press;1994;215-247.
26. Anversa P, Palackal T, Sonnenblick EH, Olivetti G, Meggs LG, Capasso JM. Myocyte cell loss and myocyte cellular hyperplasia in the hyper-trophied aging rat heart. Circ Res 1990;67:871-885.
27. Kajstura J, Cheng W, Sarangarajan R, et al. Necrotic and apoptotic myocyte death in the aging heart of Fischer 344 rat. Am J Physiol Heart Circ Physiol 1996;271:H1215-H1228.
28. Fang Z, Carlson S, Chen Y, Oparil S, Wyss J. Estrogen depletion induces NaCl-sensitive hypertension in female spontaneously hypertensive rats. Am J Physiol Regul Integr Comp Physiol 2001;281:R1934-R1939.
29. Peng N, Clark J, Wei C, Wyss J. Estrogen depletion increases blood pressure and hypothalamic norepinephrine in middle-aged spontaneously hypertensive rats. Hypertension 2003;41:1164-1167.
30. Bhuiyan MS, Shioda N, Fukunaga K. Ovariectomy augments pressure overload-induced hypertrophy associated with changes in Akt and nitric oxide synthase signaling pathways in female rats. Am J Physiol Endocrinol Metab 2007;293:E1606-E1614.
31. Fortepiani LA, Zhang H, Racusen LC, Roberts LJ II, Reckelhoff JF. Characterization of an animal model of postmenopausal hypertension in SHR. Hypertension 2003;41:640-645.
32. Hinojosa-Laborde C, Lange DL, Haywood JR. Role of female sex hormones in the development and reversal of Dahl hypertension. Hypertension 2000;35:484-489.
33. Javeshghani D, Touyz R, Sairam M, Virdis A, Neves M, Schiffrin E. Attenuated responses to angiotensin II in follitropin receptor knockout mice, a model of menopause-associated hypertension. Hypertension 2003;42:761-767.
34. Bhuiyan MS, Shioda N, Shibuya M, Iwabuchi Y, Fukunaga K. Activation of endothelial nitric oxide synthase by a vanadium compound ameliorates pressure overload-induced cardiac injury in ovariectomized rats. Hypertension 2009;53:57-63.
35. Bhuiyan MS, Shioda N, Fukunaga K. Chronic A-adrenoceptor activationY induced calpain activation and impaired eNOS-Akt signaling mediates cardiac injury in ovariectomized in female rats. Expert Opin Ther Targets 2009;13:275-286.
36. Wade GN, Zucker I. Modulation of food intake and locomotor activity in female rats by diencephalic hormone implants. J Comp Physiol Psychol 1970;72:328-336.
37. Wade GN. Some effects of ovarian hormones on food intake and body weight in female rats. J Comp Physiol Psychol 1975;88:183-193.
38. Cambotti LJ, Cole FE, Gerall AA, Frolich ED, Macphee AA. Neonatal gonadal hormones and blood pressure in the spontaneously hypertensive rat. Am J Physiol 1984;247:E258-E264.
39. Crofton JT, Share L. Gonadal hormones modulate deoxycorticosterone-salt hypertension in male and female rats. Hypertension 1997;29:494-499.
40. David FL, Carvalho MHC, Cobra ALN, et al. Ovarian hormones modulate endothelin-1 vascular reactivity and mRNA expression in DOCA-salt hypertensive rats. Hypertension 2001;38:692-696.
41. Hinojosa-Laborde C, Craig T, Zheng W, Ji H, Haywood JR, Sandberg K. Ovariectomy augments hypertension in aging female Dahl salt sensitive rats. Hypertension 2004;44:405-409.
42. Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein-kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000;6:1004-1010.
43. Fujio Y, Nguyen T, Wencker D, Kitsis RN, Walsh K. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation 2000;101:660-667.
44. Matsui T, Tao J, del Monte F, et al. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation 2001;104:330-335.
45. Kemi OJ, Celi M, Wisloff U, et al. Activation or inactivation of cardiac Akt/mTOR signaling diverges physiological from pathological hypertrophy. J Cell Physiol 2008;214:316-321.
46. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3¶-OH kinase. Nature 2000;407:538-541.
47. Camper-Kirby D, Welch S, Walker A, et al. Myocardial Akt activation and gender: increased nuclear activity in females versus males. Circ Res 2001;88:1020-1027.
48. Ren J, Hintz KK, Roughead ZK, et al. Impact of estrogen replacement on ventricular myocyte contractile function and protein kinase B/Akt activation. Am J Physiol Heart Circ Physiol 2003;284:H1800-H1807.
49. Patten RD, Pourati I, Aronovitz MJ, et al. 17 A-Estradiol reduces car-diomyocyte apoptosis in vivo and in vitro via activation of phospho-inositide-3 kinase/Akt signaling. Circ Res 2004;95:692-699.
50. Wang M, Wang Y, Weil B, et al. Estrogen receptor A mediates increased activation of PI3K/Akt signaling and improved myocardial function in female hearts following acute ischemia. Am J Physiol Regul Integr Comp Physiol 2009;296:R972-R978.
51. Hsu JT, Kan WH, Hsieh CH, Chowdhry MA, Bland KI, Chaudry IH. Mechanism of salutary effects of estrogen on cardiac function following trauma-hemorrhage: Akt-dependent HO-1 up-regulation. Crit Care Med 2009;37:1-7.
52. Bhuiyan MS, Shioda N, Fukunaga K. Targeting protein kinase B/Akt signaling with vanadium compounds for cardioprotection. Expert Opin Ther Targets 2008;12:1217-1227.
53. Bhuiyan MS, Shibuya M, Shioda N, et al. Cytoprotective effect of bis(1-oxy-2-pyridinethiolato)oxovanadiun (IV) on myocardial ischemia/reper- fusion injury is mediated by inhibition of Fas ligand and Bim expression and elevation of FLIP expression. Eur J Pharmacol 2007;571:180-188.
54. Majmudar NG, Robson SC, Ford GA. Effects of the menopause, gender, and estrogen replacement therapy on vascular nitric oxide activity. J Clin Endocrinol Metab 2000;85:1577-1583.
55. Higashi Y, Sanada M, Sasaki S, et al. Effect of estrogen replacement therapy on endothelial function in peripheral resistance arteries in normotensive and hypertensive postmenopausal women. Hypertension 2001;37:651-657.
56. Virdis A, Ghiadoni L, Pinto S, et al. Mechanisms responsible for en-dothelial dysfunction associated with acute estrogen deprivation in nor-motensive women. Circulation 2000;101:2258-2263.
57. Sanada M, Higashi Y, Nakagawa K, et al. Hormone replacement effects on endothelial function measured in the forearm resistance artery in normocholesterolemic and hypercholesterolemic postmenopausal women. J Clin Endocrinol Metab 2002;87:4634-4641.
58. Herrington DM, Espeland MA, Crouse JR 3rd, et al. Estrogen replacement and brachial artery flowYmediated vasodilation in older women. Arterioscler Thromb Vasc Biol 2001;21:1955-1961.
59. Kelemen M, Vaidya D, Waters DD, et al. Hormone therapy and antioxidant vitamins do not improve endothelial vasodilator function in postmenopausal women with established coronary artery disease: a substudy of the Women's Angiographic Vitamin and Estrogen (WAVE) trial. Atherosclerosis 2005;179:193-200.
60. Haynes MP, Sinha D, Russell KS, et al. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinaseY Akt pathway in human endothelial cells. Circ Res 2000;87:677-682.
61. Guo X, Razandi M, Pedram A, Kassab G, Levin ER. Estrogen induces vascular wall dilation: mediation through kinase signaling to nitric oxide and estrogen receptors > and A. J Biol Chem 2005;280: 19704-19710.
62. Fulton D, Gratton J-P, Sessa WC. Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough? J Pharmacol Exp Ther 2001;299:818-824.
63. Solaro RJ. Protein phosphorylation and cardiac myofilaments. In: Solaro RJ, editor. Protein Phosphorylation in Heart Muscle. Boca Raton, FL: CRC Press;1986:129-156.
64. Pabla R, Curtis MJ. Effect of endogenous nitric oxide on cardiac systolic and diastolic function during ischemia and reperfusion in the rat isolated perfused heart. J Mol Cell Cardiol 1996;28:2111-2121.
65. Schmidt HHHW, Lohmann SM, Walter U. The nitric oxide and cGMP signal transduction system: regulation and mechanism of action. Biochim Biophys Acta 1993;1178:153-175.
66. Pedram A, Razandi M, Aitkenhead M, Levin ER. Estrogen inhibits cardio-myocyte hypertrophy in vitro. Antagonism of calcineurin-related hypertrophy through induction of MCIP1. J Biol Chem 2005;280:26339-26348.
67. Donaldson C, Eder S, Baker C, et al. Estrogen attenuates left ventricular and cardiomyocyte hypertrophy by an estrogen receptorYdependent pathway that increases calcineurin degradation. Circ Res 2009;104:265-275.
68. Rothermel BA, Vega RB, Yang J, Wu H, Bassel-Duby R, Williams RS. A protein encoded within the Down syndrome critical region is enriched in striated muscles and inhibits calcineurin signaling. J Biol Chem 2000;275:8719-8725.
69. Yang J, Rothermel B, Vega RB, et al. Independent signals control expression of the calcineurin inhibitory proteins MCIP1 and MCIP2 in striated muscles. Circ Res 2000;87:e61-e68.
70. Rothermel BA, McKinsey TA, Vega RB, et al. Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A 2001;98:3328-3333.
71. Sanna B, Brandt EB, Kaiser RA, et al. Modulatory calcineurin-interacting proteins 1 and 2 function as calcineurin facilitators in vivo. Proc Natl Acad Sci U S A 2006;103:7327-7332.
72. Braz JC, Bueno OF, De Windt LJ, Molkentin JD. PKC > regulates the hypertrophic growth of cardiomyocytes through extracellular signal-regulated kinase 1/2 (ERK1/2). J Cell Biol 2002;156:905-919.
73. Sanna B, Bueno OF, Dai YS, Wilkins BJ, Molkentin JD. Direct and indirect interactions between calcineurin-NFAT and MEK1-extracellular signal-regulated kinase 1/2 signaling pathways regulate cardiac gene expression and cellular growth. Mol Cell Biol 2005;25:865-878.
74. Ciric O, Susic D. Effect of isoprenaline on blood pressure and heart rate in different phases of the oestrous cycle. Endokrinologie 1980;76:274-278.
75. Thawornkaiwong A, Preawnim S, Wattanapermpool J. Upregulation of A 1-adrenergic receptors in ovariectomized rat hearts. Life Sci 2003; 72:1813-1824.
76. 2+ channels in the heart from ovariectomized rats. Br J Pharmacol 2005;144:972-981.